Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Attralus

    Client Virtual Booth

    ATTRALUS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Attralus
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    ‍329 Oyster Point Blvd Third Floor South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://attralus.com/
    Linkedin
    Linkedin
    Twitter
    Twitter
    https://twitter.com/attralus

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Attralus Closes $56 Million Financing
    Attralus Closes $56 Million Financing

    https://www.globenewswire.com//news-release/2024/02/06/2824129/0/en/Attralus-Closes-56-Million-Financing.html

    GLOBENEWSWIRE
    06 Feb 2024
    Share Share
    Attralus Announces Publication of Studies Evaluating Iodine (124I) Evuzamitide
    Attralus Announces Publication of Studies Evaluating Iodine (124I) Evuzamitide

    https://www.globenewswire.com//news-release/2023/11/07/2774920/0/en/Attralus-Announces-Publication-of-Two-Studies-Evaluating-Iodine-124I-Evuzamitide-AT-01-using-PET-CT-in-the-Journal-of-American-College-of-Cardiology-JACC-CV-Imaging.html

    GLOBENEWSWIRE
    07 Nov 2023
    Share Share
    Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01)
    Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01)

    https://www.globenewswire.com//news-release/2023/10/02/2752602/0/en/Attralus-Announces-Presentation-of-Clinical-Data-for-124I-Evuzamitide-AT-01-a-Novel-Amyloid-Specific-PET-Imaging-Agent-at-the-28th-Annual-Scientific-Session-of-the-American-Society.html

    GLOBENEWSWIRE
    02 Oct 2023
    Share Share
    Attralus Presents New Preclinical Data on AT-04 and AT-07
    Attralus Presents New Preclinical Data on AT-04 and AT-07

    https://www.globenewswire.com/news-release/2023/04/03/2639387/0/en/Attralus-Presents-New-Preclinical-Data-on-AT-04-and-AT-07-Pan-Amyloid-Removal-Therapeutics-Targeting-Neurodegenerative-Disorders-at-AD-PD-2023.html

    GLOBENEWSWIRE
    03 Apr 2023
    Share Share
    Attralus Receives FDA and EMA Orphan Designation for AT-01
    Attralus Receives FDA and EMA Orphan Designation for AT-01

    https://www.globenewswire.com/news-release/2022/12/19/2576139/0/en/Attralus-Receives-FDA-and-EMA-Orphan-Designation-for-AT-01-Iodine-I-124-Evuzamitide-an-Investigational-Diagnostic-for-the-Management-of-AL-and-ATTR-Amyloidosis.html

    GLOBENEWSWIRE
    19 Dec 2022
    Share Share
    Attralus &Ossianix Announce an Option and License Agreement using the TXP1
    Attralus &Ossianix Announce an Option and License Agreement using the TXP1

    https://www.globenewswire.com/news-release/2022/11/17/2558010/0/en/Attralus-and-Ossianix-Announce-an-Option-and-License-Agreement-using-the-TXP1-Brain-Shuttle-for-Targeted-Delivery-of-AT-04-a-Pan-Amyloid-Removal-Therapeutic-for-Neurodegenerative-D.html

    GLOBENEWSWIRE
    17 Nov 2022
    Share Share
    Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02
    Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02

    https://www.globenewswire.com/news-release/2022/10/17/2535290/0/en/Attralus-Announces-First-Subject-Enrolled-in-Phase-1-Clinical-Trial-of-AT-02-Its-Lead-Pan-Amyloid-Removal-Therapeutic-Candidate.html

    GLOBENEWSWIRE
    17 Oct 2022
    Share Share
    Attralus doses first subject in Phase I pan-amyloid removal therapy trial
    Attralus doses first subject in Phase I pan-amyloid removal therapy trial

    https://www.clinicaltrialsarena.com/news/attralus-par-therapy-trial/

    CLINICALTRIALSARENA
    17 Oct 2022
    Share Share
    Attralus Announces New Clinical Data in ATTR CM and AL With AT-01
    Attralus Announces New Clinical Data in ATTR CM and AL With AT-01

    https://www.globenewswire.com/news-release/2022/09/12/2513836/0/en/Attralus-Announces-New-Clinical-Data-in-ATTR-CM-and-AL-With-AT-01-Iodine-I-124-Evuzamitide-a-Novel-Amyloid-Specific-Imaging-Agent.html

    GLOBENEWSWIRE
    12 Sep 2022
    Share Share
    Attralus Announces New Preclinical Demonstrating Novel Human Chimeric (CAR-M)
    Attralus Announces New Preclinical Demonstrating Novel Human Chimeric (CAR-M)

    https://www.globenewswire.com/news-release/2022/09/06/2510454/0/en/Attralus-Announces-New-Preclinical-Data-Demonstrating-Novel-Human-Chimeric-Antigen-Receptor-Macrophages-CAR-M-for-Potential-Amyloid-Removal-at-18th-International-Symposium-on-Amylo.html

    GLOBENEWSWIRE
    06 Sep 2022
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search